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Abstract 
Aim: The aim of this study is to estimate the population level ‘cure’ of Maltese colorectal cancer patients 
diagnosed from 1995 to 2004, and to estimate the median survival time for the ‘uncured’ patients.  
Methods and study population: Analysis was conducted on 1,470 cases registered by the Malta National 
Cancer Register between 1995 and 2004 followed up to end of 2010. The mean age of the patients was 
66.4 (95% CI 65.8 – 67.1) with an equal number of men and women. Background mortality for 1995 to 
2010 was extracted from publicly available life tables. A mixture model with Weibull survival distribution 
and identity link was used to model ‘cure’. Results:  The overall ‘cured’ proportion for the patients 
diagnosed in 1995 – 1999 was 45.3% (95% CI 40.2 – 50.5) while the ‘cured’ proportion for the patients 
diagnosed in 2000 – 2004 was 52.3% (95% CI 47.2 – 57.5).  Median survival time for the ‘uncured’ 
increased in the second calendar period from 1.25 years (95% CI 1.04 – 1.45) to 1.42 years (95% CI 1.15 – 
1.76). Conclusion: In Malta, like the rest of Europe, improvements have been made in short and long term 
survival over a 15 year period under study. To continue this improvement, differences by age that still 
persist must be investigated and efforts focused to reduce any gaps between Malta and other European 
countries.  
 
Keywords: Statistical cure, colorectal neoplasms, relative survival, population based registry 
 
 
 
 
3 
 
1. Introduction 
Cancer is one of the leading causes of death worldwide and colorectal cancer is the fourth most common 
cause of cancer death. It is estimated that in Europe there were 214,700 deaths from colorectal cancer 
(12.3% of all cancer deaths) in 2012 (1). In Malta, in 2013, colorectal cancer was the second leading cause 
of cancer death amongst both men and women (2).  
Relative survival analysis present survival estimates adjusted for the background risk of death at particular 
time points after diagnosis. An extension of the relative survival concept is the notion of ‘statistical cure’ 
or ‘population cure’. This is defined at a group level and is different from the concept of individual cure 
where patients can be considered medically free of cancer (3). ‘Population cure’ relates to the tendency 
for some cancer relative survival curves to reach a plateau after a period of follow-up. This indicates that 
the excess mortality attributed to the cancer of the patient is equal to their background mortality and 
thus these cancer patients are no more likely to die than their counterparts in the general population. The 
analysis of ‘cure’ can expand our understanding of the pattern of cancer survival.  
The EUROCARE project estimated the ‘cured’ proportion in Europe for patients diagnosed between 1978 
and 1999 (4, 5) and found a 12% improvement in long term survival for the ‘cured’ proportion from 36% 
in 1978-1985, to 48.5% in 1997-1999.  The study also showed a strong negative association between age 
and ‘cure’. Studies conducted in Sweden, Finland and North West England have also made use of ‘cure’ 
models to assess survival trends for colorectal cancer and found similar results (6-8)  
 
The aim of this study was to estimate the proportion of Maltese colorectal patients diagnosed from 1995 
to 2004, who were statistically ‘cured’ and to estimate the median survival time for the uncured. This 
study is the first to apply ‘cure’ models on data from the Malta National Cancer Register.  
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2. Materials and Methods 
2.1. Data sources 
The data used in this study was taken from the Malta National Cancer Register which collects data for all 
incident cancers in the population resident in Malta and Gozo (9). Cancer notification is compulsory by 
the Notification of Cancer Act of 1957 (10). Data were collected for all patients diagnosed with colorectal 
cancer from 1995 to 2004 and followed up to the end of 2010. Colorectal cancers are coded by the registry 
using the International Classification of Diseases for Oncology (ICD-O-2) and codes C18 – C20 were 
included in this study.  
Background mortality for the years 1995 to 2010 were obtained from life tables available publicly from 
the National Statistics Office. In these tables age is truncated to 85+ up to 1998 and 90+ from 1999 
onwards. Since the risk of death increases exponentially after 85 years of age and because our cancer 
patients were aged up to 97 at the end of follow-up, it was necessary to impute age and sex specific rates 
of death for the older ages, for each of the years of follow-up. The available life tables were thus extended 
and smoothed up to 100 years of age using the Ewbank four parameter method (11), separately by year 
and gender. The standard life table used to smooth the data was that available for England and Wales 
from 1998 to 2000 since no reliable standard was available for Malta. To assess the goodness of fit of the 
derived life tables; the smoothed mortality rates and survival function in each table were plotted against 
the observed mortality rates. 
2.2 Study population 
In total 1,496 patients were eligible for analysis in this study. Of these, 25 were excluded because they 
were diagnosed only at death via death certificate (1.7%). Further to this, 1 more case was excluded since 
region of residence was unknown. In total 1,470 cases were examined. For each patient sex, age at 
diagnosis, date of diagnosis, date of death and region of residence were collected. Age at diagnosis was 
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grouped into 4 categories - <55, 55 – 64, 65 – 74 and 75+ years; while year of diagnosis was collapsed into 
two broad cohorts – 1995 – 1999 and 2000 – 2004.  Vital status and date of death is collected by the 
registry through death certificates and linkage with the National Mortality Register. Since no variables 
directly measuring socioeconomic status were available, region of residence was used as a proxy for socio-
economic status. The National Statistics Office (NSO) classifies the Maltese Islands into six broad 
geographic regions– the North Harbour, South Harbour, South East, West, North and Gozo.  The North 
Harbour is the largest region with 28.9% of the total resident Maltese population living here while Gozo, 
Malta’s sister island, is the smallest region at 7.5% (12).  Studies on income and living conditions 
consistently show differences across region.  The South Harbour region exhibits the highest percentage 
at risk of poverty and the lowest average household income (13).  
 
2.3. Statistical analysis 
The relative survival ratio (or relative survival), is a measure of survival from a particular disease of interest 
(e.g. cancer) in the absence of other causes of death.  In our context, relative survival is the ratio of the 
survival observed among the cancer patients and the survival that would have been expected if they had 
experienced the same death rates as the general population from which they derive.  Relative survival by 
age group, sex, calendar period of diagnosis and region of residence was estimated  using the Ederer II 
method(14).  
 
Cure models estimate the proportion ‘cured’ of their cancer; that is, the proportion of patients who 
experience no long-term disease related (excess) mortality. These models are only appropriate when it is 
believed that ‘cure’ is a reasonable assumption. This can be established by visual inspection of relative 
survival curves. A mixture model, which assumed a Weibull distribution and an identity link, was used to 
estimate ‘cure’.  We used the model estimates to derive a) the proportion ‘cured’; b) the relative survival 
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curves for both the whole sample and the ‘uncured’ patients; and c) the median survival time of the 
‘uncured’.  Estimation of the model parameters was obtained using the maximum likelihood method on 
individual-patient records.   
 
The modelling strategy aimed to develop a parsimonious model to predict ‘cure’.  Initially all co-variables, 
as well as an interaction term between age group and year of diagnosis, were included to estimate the 
‘cure’ fraction and two Weibull parameters.  The likelihood ratio test was used to assess the number of 
co-variables included in the model.  We also tested whether the Weibull shape and scale parameters 
varied by the co-variables included in the final model.   In order to assess the fit of the final model, survival 
curves were derived from the model estimates and were compared graphically to the estimates obtained 
using the Ederer II method.    All analyses were performed using Stata version 11. strsmix (3) was used to 
model cure. 
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3. Results 
The mean age of the patients was 66.4 (95% CI 65.8 – 67.1). The proportion of men and women was similar 
in the two periods. Distribution of patients across the six regions reflects the relative population sizes of 
the regions (Table 1).  
 
Five year relative survival for the whole study population (1995 – 2004) was 53.3% (95% CI 50.3 – 56.3). 
Survival estimates were similar for men and women and by period of diagnosis.  The curves by age group 
indicated lower survival in the older age groups. Five year survival amongst those diagnosed at age 55 or 
younger was 63.3% (95% CI 58% - 68.2%) while for those diagnosed age 75+ survival was 47.2% (95% CI 
41.5% - 52.9%).  Due to small numbers with increasing years of follow up, relative survival showed wider 
variability after 11 years of follow up especially when subdividing by multiple categories such as region 
and age group (Figure 1).  
On visual inspection, ‘cure’ did not appear to have been attained for the oldest age group (75+) therefore 
this group was excluded from the ‘cure’ analysis (1054 patients analysed). Initially all co-variables (age 
group, sex, region and year of diagnosis) were included in the model, with an interaction term between 
age and year of diagnosis.  We found no association between the ‘cured’ proportion and sex (p=0.32) or 
region of residence (North reference group; North Harbour p=0.68; South East p=0.80; South Harbour 
p=0.64; West p=0.37 and Gozo p=0.52). Since the relative survival curves in general show better survival 
for Gozo compared to the five other regions forming the island of Malta, another regional categorization 
was created to compare Gozo to Malta (North Harbour, South Harbour, South East, North and West 
combined). However this new regional distribution did not improve the fit of the model, although the 
association between the cured proportion for the two islands was borderline significant (p=0.07).  Our 
final model included age group, year of diagnosis and the interaction between age group and year of 
diagnosis. Allowing the scale parameter to vary by age group, year of diagnosis and the interaction term 
8 
 
improved the fit of the model (p<0.01), whereas this was not the case for the estimate of the shape 
parameter (p=0.86).  
 
The overall proportion ‘cured’ for the age group 55 to 64 was 12% lower when compared to those aged 
less than 55 (p=0.062 ),indicating a possible association . Figure 2 and 3 show the modelled estimates of 
relative survival for the total population together with the Ederer II estimates of relative survival with 
corresponding 95% confidence intervals by age and year of diagnosis.  
 
Table 2 shows modeled estimates of the ‘cured’ proportion by age and year of diagnosis. The overall 
‘cured’ proportion was 45.3% (95% CI 40.2 – 50.5) for the patients diagnosed in 1995 – 1999 and 52.3% 
(95% CI 47.2 – 57.5) for the patients diagnosed in 2000 – 2004.  The higher cure proportion in the recent 
period suggests improvement with time (z-test p<0.05), which is primarily due to the improvements seen 
in the youngest and middle age groups. 
 
In the ‘uncured’ group, we found evidence of a difference for patients aged 65 – 74 compared to those 
aged less than 55 (p<0.01).  Older patients within the ‘uncured’ group exhibited poorer survival.  Figure 4 
shows the modelled estimates of relative survival for the ‘uncured’ proportion for both calendar periods 
separately. 
 
Table 3 shows the modeled estimates of median survival time of the ‘uncured’ group by age and year of 
diagnosis. Median survival time in the ‘uncured’ group increased from 1.25 years (95% CI 1.04 – 1.45) in 
1995-1999 to 1.42 years (95% CI 1.15 – 1.76) for patients diagnosed in 2000 - 2004. The median survival 
was lowest in patients aged 65-74 years; 0.80 years (95% CI 0.60 – 1.08) in 1995 – 1999 and 1.07 years 
(95% CI 0.80 – 1.43) in 2000 – 2004.  
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4. Discussion 
This is the first study on population ‘cure’ for colorectal cancer in Malta. Comparable European level ‘cure’ 
estimates are only available for the period from 1994 to 1999 (5). The proportion of ‘cured’ patients in 
Malta for this same period was 45.3% (95% CI 40.2 – 50.5).  The median survival time for the ‘uncured’ 
group was 1.25 years (95% CI 1.04 – 1.45). The proportion ‘cured’ in our study is slightly lower than the 
European estimate from the EUROCARE data for 1994 to 1999; 46.8% for patients in 1994 – 1996 (95% CI 
45.5 – 48.1) and 48.5% for patients in 1997 – 1999 (95% CI 45.6 – 51.4). It is unclear if the results for the 
recent period (2000 – 2004) are similar to the European estimates since no comparable ‘cure’ data is 
available at this time. Comparison of the median survival time could not be conducted since mean rather 
than median time was calculated by the authors of the EUROCARE study (5).    
Age at diagnosis and calendar period of diagnosis are the two main factors associated with survival 
amongst patients diagnosed with colorectal cancer in Malta between 1995 and 2004. Sex does not 
influence ‘cure’ in Malta despite the fact that studies suggest that females have an advantage in colorectal 
survival in Europe (15). This could partly be due to the smaller number of patients in Malta when 
compared to the large pooled dataset used by the EUROCARE. An internal analysis conducted by the Malta 
National Cancer Register for colorectal cancer patients diagnosed between 1999 and 2002 showed that 
women were diagnosed at a more advanced stage when compared to men which may cancel out any 
advantage associated with being female (16). The EUROCARE study suggests that a reason for the 
advantage may be due to differences in age at diagnosis. In our Maltese study population we did not find 
evidence of a difference in age at diagnosis by sex (p=0.83). While research conducted on socioeconomic 
differences in relative survival and ‘cure’ have shown major gaps amongst low and high socio-economic 
strata (6, 17), regional differences were not found in this study. However, this must be taken with caution 
since region of residence may be too broad to act as a proxy for socio-economic status even though studies 
show that there are differences in income and poverty levels at the regional level (13). A lack of regional 
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differences may suggest that the small size of the island allows for better physical access to care and 
highlights the universal and free for all availability of oncology care in the national health system.  On the 
other hand regions may be too large to truly measure finer socio-economic differences. The North 
Harbour region of Malta, for example, encompasses nearly 30% of the population. A composite indicator 
at post code level containing data on factors such as education level, employment and deprivation may 
better outline differences between population sub-groups. If this data were available, analysis on socio-
economic differences in survival would allow for richer understanding of survival.  Indeed while it is true 
that oncology treatment is available to all patients in Malta, the fact that there is only one service provider 
offers no choice for patients and Malta, being an island, is restricted with respect to cross-border care 
options. These factors, though difficult to investigate, must be considered when comparing Malta to other 
larger European countries.  
Amongst the oldest group (75 years and over); it seems that the survival curve did not show a plateau 
even after 15 years of follow up. The relative survival curve patterns may be explained by the small 
numbers of patients in our study or it may be indicating that patients over the age of 75 remain with 
elevated risk of death even after 10 years of follow up.  The data suggest that while patients aged 55 to 
64 experience better survival than their older counterparts in the short term (up to 5 years after 
diagnosis), these gains in survival do not persist over time. Patients in this age group take longer to reach 
‘cure’ indicating that their elevated risk of death remains comparably high. The explanation for this is 
unclear. It may be due to different stage at diagnosis by age or possibly the treatment protocols used 
locally. At the time of analysis comprehensive data on stage were not available.  While notification of 
cancer cases is governed through a legal act, the law does not stipulate the compulsory collection of data 
such as stage or treatment.  Published reviews on treatment practices in Malta are limited and an 
adequate review of diagnosis and treatment protocols, which may influence survival outcomes, is not 
available. A study by Brincat and colleagues (18) reviewed recurrence of rectal cancer in patients 
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diagnosed in 2001 – 2003 with the specific aim of reviewing treatment and management protocols. The 
study found a local recurrence rate of 16% which was noted to be “disappointingly” high when compared 
to other studies using different treatment protocols. The authors suggest a need to implement new 
treatment protocols using appropriate imaging followed by the referral of selected patients for pre-
operative radiation or chemo-radiation and adequate surgery. Since no other studies were found 
following this publication, it is not clear if new protocols have been put into place for the treatment and 
management of rectal cancer following this audit. The outcomes of this present study may also be related 
to other factors that have not been considered here, however it seems clear that this age group should 
be the topic of further research. 
 
Analysis of cancer data in Malta are based on a small number of patients due to the small population size 
and this is evident when analysis is conducted across multiple categories and after extended follow-up. 
To mitigate the problem, categories for age, year of diagnosis and follow up time were compiled in such 
a way that they made sense for the purpose of comparison, while being large enough to ensure statistical 
power. A limitation of this study is the fact that background mortality smoothing had to be conducted 
against a standard population that was not a Maltese population, though the smoothed data for all the 
tables fitted the observed data well after smoothing.  It would have been better to have had regional life 
tables to adjust for regional differences in background mortality. However, it was not possible to produce 
these since data on mortality at regional level are not available. One of the major strengths of this study 
is that the data analysed represent coverage of the entire national population. According to EUROCARE, 
the average percentage coverage of the population of the cancer registries in Southern Europe (36%) is 
far lower than the coverage of registries in Northern Europe, Ireland and the UK (all with 100%)(19). This 
research therefore is a valuable source of information available on national level survival in Southern 
Europe. 
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While improvements have been made in survival over the past 15 years, the data suggests that age 
differences still persist for both short term and long term survival and need to be investigated further. 
The ‘cure’ models in this study have outlined that the technique can be incorporated into survival analysis 
as a complimentary and informative method of measuring progress in cancer survival. The ‘cure’ models 
have also highlighted the importance of looking at long-term survival as a measure of improvement in 
survival and not just focusing on the benchmark of 5 year survival that is usually taken when comparing 
results over time.  
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Table 1: Patient characteristics 
  
 
 
  
    Year of Diagnosis 
    1995 - 1999 2000 - 2004 Total 
    N (%) N (%) N (%) 
 
Total  658 (45) 812 (55) 1,470 (100) 
        
Characteristic Category       
 
Age  (years) <55 127 (19) 139 (17) 266 (18) 
 55 - 64 148 (22) 185 (23) 333 (23) 
 65 - 74 195 (30) 260 (32) 455 (31) 
  75+ 188 (29) 228 (28) 416 (29) 
 
Sex Male 324 (49) 418 (51) 742 (50) 
  Female 334 (51) 394 (49) 728 (50) 
 
Region North 56 (9) 95 (12) 151 (10) 
 North Harbour 222 (34) 279 (34) 501 (34) 
 South East 76 (12) 108 (13) 184 (13) 
 South Harbour 151 (23) 174 (21) 325 (22) 
 West 88 (13) 86 (11) 174 (12) 
  Gozo 65 (10) 70 (9) 135 (9) 
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Table 2: Predicted proportion ‘cured’ in 1995 - 1999 and 2000 - 2004, by age.  Z-test compares 
proportions for total and age groups across year of diagnosis. 
 
    Year of Diagnosis  
  1995 - 1999 2000 – 2004  
  
Proportio
n ‘cured’ 
% 
95% CI 
Proportio
n ‘cured’ 
% 
95% CI 
z-test  
Total 
 
45.3 40.2 – 50.5 52.3 47.2 – 57.5 p=0.008 
       
 <55 47.4 38.2 - 56.5 58.0 46.5 - 69.6 p=0.08 
Age 
(years) 55 - 64 35.3 26.4 – 44.2 49.9 41.4 – 58.4 
p=0.007 
  65 - 74 53.1 45 – 61.2 50.9 43.3 – 58.5 p=0.65 
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Table 3: Median survival time of the “uncured” in 1995 - 1999 and 2000 - 2004 by age  
    Year of Diagnosis 
  1995 - 1999 2000 – 2004 
  
Median survival 
time of uncured 
(years) 
95% CI 
Median 
survival time of 
uncured (years) 
95% CI 
      
Total  1.25 1.04 – 1.45 1.42 1.15 – 1.76 
      
 <55 1.32 0.96 – 1.81 2.40 1.39 – 4.16 
Age (years) 55 - 64 1.71 1.29 – 2.29 1.46 1.06 - 2.02 
  65 - 74 0.80 0.60 - 1.08 1.07 0.80 - 1.43 
      
 
 
 
 
 
Figure 1: Relative Survival Ratio (%) up to 16 years after diagnosis (a) by gender (b) by region of 
residence (c) by year of diagnosis (d) by age at diagnosis 
 
Figure 2: Relative Survival Ratio (%) estimates derived from the model and using Ederer II with 
corresponding 95% CI for patients diagnosed 1995-1999, by age at diagnosis.  Horizontal lines indicate 
point where statistical cure is reached. 
 
Figure 3: Relative Survival Ratio (%) estimates derived from the model and using Ederer II with 
corresponding 95% CI for patients diagnosed 2000-2004, by age at diagnosis.  Horizontal lines indicate 
point where statistical cure is reached. 
 
Figure 4: Relative Survival Ratio (%) estimates for the uncured patients only derived from the model.  
Vertical lines indicate median survival time. 
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